US HB447 | 2019-2020 | 116th Congress
Status
Spectrum: Partisan Bill (Democrat 27-0)
Status: Introduced on January 10 2019 - 25% progression, died in committee
Action: 2019-01-25 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on January 10 2019 - 25% progression, died in committee
Action: 2019-01-25 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Addresses the importation of drugs from Canada and other foreign countries. The bill requires the Food and Drug Administration (FDA) to promulgate regulations within 180 days permitting wholesalers, pharmacies, and individuals to import certain prescription drugs from Canada. After two years, The FDA, may permit the importation of prescription drugs from other countries. The bill establishes a process for certifying foreign sellers—a licensed foreign pharmacy or foreign wholesale distributor.
Title
Affordable and Safe Prescription Drug Importation Act
Sponsors
Rep. Elijah Cummings [D-MD] | Rep. Lloyd Doggett [D-TX] | Sen. Peter Welch [D-VT] | Rep. Steve Cohen [D-TN] |
Rep. Ro Khanna [D-CA] | Rep. Barbara Lee [D-CA] | Rep. Eleanor Norton [D-DC] | Rep. Chellie Pingree [D-ME] |
Rep. Rosa DeLauro [D-CT] | Rep. Brad Sherman [D-CA] | Rep. Mark Pocan [D-WI] | Rep. Pramila Jayapal [D-WA] |
Rep. Ilhan Omar [D-MN] | Rep. Raja Krishnamoorthi [D-IL] | Rep. Tulsi Gabbard [D-HI] | Rep. James Langevin [D-RI] |
Rep. Sheila Jackson-Lee [D-TX] | Rep. Earl Blumenauer [D-OR] | Rep. Janice Schakowsky [D-IL] | Rep. Joseph Neguse [D-CO] |
Rep. Alexandria Ocasio-Cortez [D-NY] | Rep. Rashida Tlaib [D-MI] | Rep. Mark DeSaulnier [D-CA] | Rep. Debra Haaland [D-NM] |
Rep. Jamie Raskin [D-MD] | Rep. Grace Napolitano [D-CA] | Rep. John Garamendi [D-CA] |
History
Date | Chamber | Action |
---|---|---|
2019-01-25 | House | Referred to the Subcommittee on Health. |
2019-01-10 | House | Referred to the House Committee on Energy and Commerce. |
2019-01-10 | House | Introduced in House |
Same As/Similar To
SB97 (Same As) 2019-01-10 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
HB1478 (Related) 2019-03-01 - Referred to the Subcommittee on Health.
SB1801 (Related) 2019-06-12 - Read twice and referred to the Committee on Finance.
HB1478 (Related) 2019-03-01 - Referred to the Subcommittee on Health.
SB1801 (Related) 2019-06-12 - Read twice and referred to the Committee on Finance.
Subjects
Administrative law and regulatory procedures
Canada
Congressional oversight
Department of Health and Human Services
Drug safety, medical device, and laboratory regulation
Government information and archives
Government studies and investigations
Health
Prescription drugs
Trade restrictions
User charges and fees
Canada
Congressional oversight
Department of Health and Human Services
Drug safety, medical device, and laboratory regulation
Government information and archives
Government studies and investigations
Health
Prescription drugs
Trade restrictions
User charges and fees
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/116th-congress/house-bill/447/all-info |
Text | https://www.congress.gov/116/bills/hr447/BILLS-116hr447ih.pdf |